Anti-SARS-CoV-2 VHH and C7C peptide fused with Angiopep-2 efficiently traverse blood-brain barrier model and neutralizes virus

IntroductionThe therapy for SARS-CoV-2-related CNS infection relies on treating neuroinflammation and associated damage, rather than a specific antiviral. The lack of specific antiviral therapeutics is mainly attributed to the limited permeability of drugs across the blood-brain barrier.MethodsIn this paper, we present a detailed pipeline for selecting VHHs (single variable domain of llama heavy chain antibody) and 7-mer cyclic peptides (C7C) from phage-display libraries that bind to the spike p